硫酸镁与血肿扩大:FAST-MAG随机试验的辅助分析
该辅助分析基于FAST-MAG随机试验中268例急性脑出血患者,比较院前2小时内静脉硫酸镁与安慰剂对血肿扩大及功能结局的影响。结果显示两组血肿体积、血肿扩大及3个月改良Rankin量表评分3-6分比例均无统计学差异。作者结论为硫酸镁未减少血肿扩大或改善90天功能结局,初始低镁血症患者的获益未被评估。
要点
- 在268例急性脑出血患者中,硫酸镁组与安慰剂组血肿扩大体积无统计学差异。
- 两组3个月改良Rankin量表评分3-6分比例无统计学差异(59%对50%,P=0.5)。
- 作者结论为硫酸镁未减少血肿扩大或改善90天功能结局。
核心结论
- 硫酸镁未减少血肿扩大或改善90天功能结局。
- 初始低镁血症患者的获益未被评估。
研究设计与样本
- 对FAST-MAG随机试验中前瞻性收集的数据进行回顾性分析。
- 纳入268例符合研究入组标准的脑出血患者,平均年龄65.4±13/4岁,女性占33%,211例(79%)有高血压病史。
- 患者在意起病2小时内接受静脉硫酸镁或匹配安慰剂治疗。
- 采用Mann-Whitney U检验比较两组血肿扩大、神经功能缺损严重程度(美国国立卫生研究院卒中量表)和3个月整体残疾(改良Rankin量表)。
主要发现
- 到达时血肿体积:硫酸镁组10.1(5.6-28.7)mL vs 安慰剂组12.4(5.6-28.7)mL(P=0.6),两组无统计学差异。
- 血肿扩大:硫酸镁组2.0(0.1-7.4)mL vs 安慰剂组1.5(-0.2至8)mL(P=0.5),两组无统计学差异。
- 3个月改良Rankin量表评分3-6分比例:硫酸镁组59% vs 安慰剂组50%(P=0.5),两组无统计学差异。
- 首次扫描后随访脑影像的中位时间为17.1(11.3-22.7)小时。
- 现场洛杉矶运动量表初始缺损严重程度中位数为4(3-5),到院早期美国国立卫生研究院卒中量表评分中位数为16(9.5-25.5)。
局限性
- 初始低镁血症患者的获益未被评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intracerebral hemorrhage (ICH) is the deadliest form of stroke. In observational studies, lower serum magnesium has been linked to more hematoma expansion (HE) and intracranial hemorrhage, implying that supplemental magnesium sulfate is a potential acute treatment for patients with ICH and could reduce HE. FAST-MAG (Field Administration of Stroke Therapy - Magnesium) was a clinical trial of magnesium sulfate started prehospital in patients with acute stroke within 2 hours of last known well enrolled. CT was not required prior to enrollment, and several hundred patients with acute ICH were enrolled. In this ancillary analysis, we assessed the effect of magnesium sulfate treatment upon HE in patients with acute ICH. METHODS: We retrospectively analyzed data that were prospectively collected in the FAST-MAG study. Patients received intravenous magnesium sulfate or matched placebo within 2 hours of onset. We compared HE among patients allocated to intravenous magnesium sulfate or placebo with a Mann-Whitney U. We used the same method to compare neurological deficit severity (National Institutes of Health Stroke Scale) and global disability (modified Rankin Scale) at 3 months. RESULTS: Among 268 patients with ICH meeting study entry criteria, mean 65.4±13/4 years, 33% were female, and 211 (79%) had a history of hypertension. Initial deficit severities were median (interquartile range) of 4 (3-5) on the Los Angeles Motor Scale in the field and National Institutes of Health Stroke Scale score of 16 (9.5-25.5) early after hospital arrival. Follow-up brain imaging was performed a median of 17.1 (11.3-22.7) hours after first scan. The magnesium and placebo groups did not statistically differ in hematoma volume on arrival, 10.1 (5.6-28.7) versus 12.4 (5.6-28.7) mL (P=0.6), or HE, 2.0 (0.1-7.4) versus 1.5 (-0.2 to 8) mL (P=0.5). There was no difference in functional outcomes (modified Rankin Scale score of 3-6), 59% versus 50% (P=0.5). CONCLUSIONS: Magnesium sulfate did not reduce HE or improve functional outcomes at 90 days. A benefit for patients with initial hypomagnesemia was not addressed. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT00059332.
引用
- Naidech AM, Shkirkova K, Villablanca JP, et al. Magnesium Sulfate and Hematoma Expansion: An Ancillary Analysis of the FAST-MAG Randomized Trial. Stroke. 2022. PMID: 35380053. doi:10.1161/STROKEAHA.121.037999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。